Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.

Mavupharma Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://mavupharma.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address5400 Carillon PointBuilding 5000 4th FloorKirkland, WA 98033WashingtonUnited States
5400 Carillon PointBuilding 5000 4th FloorKirkland, WA 98033
Washington
United States
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]